The shares of Zydus Lifesciences declined 2% to Rs 1,058 on the BSE on Wednesday after the company announced that it has completed the acquisition of US-based pharma company Assertio Holdings Inc. for $166.4 million.
In an exchange filing released on Tuesday, Zydus Lifesciences said that it has successfully completed the cash tender offer through its wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding shares of common stock of Assertio Holdings Inc.